Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

Q: What does CUSIP 98422T100 represent in this 13F holders report?

CUSIP 98422T100 is the security identifier for XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share in Q2 2024?

31 institutional investors reported XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share for Q2 2024. Use the holders table for investor-level position and value details.

CUSIP: 98422T100

Q2 2024 13F Holders as of 30 Jun 2024

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 73,644,024
Total 13F shares: 14,508,823
Share change: +2,037,654
Total reported value: $13,746,216
Price per share: $0.95
Number of holders: 31
Value change: +$1,785,264
Number of buys: 16
Number of sells: 12

Quarterly Holders Quick Answers

What is CUSIP 98422T100?
CUSIP 98422T100 identifies XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2024
Previous quarter: Q1 2024

Recent filing periods for CUSIP 98422T100:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Yekaterina Chudnovsky	3/4/5	10%+ Owner	— class O/S missing	7,000,000	$5,320,000	—	07 Jun 2024	3/4/5
Bain Capital Life Sciences Investors, LLC	13F 3/4/5	Company · 10%+ Owner	3.8%	2,805,413	$3,029,846	—	31 Mar 2024	13F 3/4/5
SV7 Impact Medicine Fund LP	3/4/5	10%+ Owner	— class O/S missing	3,227,264	$2,678,630	—	26 Oct 2021	3/4/5
FMR LLC	13F 3/4/5	Company · Other*	2.6%	1,907,671	$2,060,285	—	31 Mar 2024	13F 3/4/5
James E. Flynn	3/4/5	Possible Member of 10% Group, 10%+ Owner	— class O/S missing	2,287,944	$1,898,994	—	26 Oct 2021	3/4/5
Atlas Venture Fund XI, L.P.	3/4/5	10%+ Owner	— class O/S missing	2,754,109	$1,762,629	—	08 Feb 2024	3/4/5
TAKEDA PHARMACEUTICAL CO LTD	13F 3/4/5	Company · 10%+ Owner	2%	1,475,121	$1,593,131	—	31 Mar 2024	13F 3/4/5
RiverVest Venture Management LLC	13F	Company	2%	1,441,444	$1,556,790	—	31 Mar 2024	13F
Rock Springs Capital Management LP	13F 3/4/5	Company · 10%+ Owner	2%	1,440,759	$1,556,020	—	31 Mar 2024	13F 3/4/5
RiverVest Venture Fund IV, L.P.	3/4/5	10%+ Owner	— class O/S missing	1,441,444	$1,196,399	—	26 Oct 2021	3/4/5
Atlas Venture Life Science Advisors, LLC	13F	Company	1.3%	992,912	$1,072,345	—	31 Mar 2024	13F
VANGUARD GROUP INC	13F	Company	1.2%	902,531	$974,734	—	31 Mar 2024	13F
BAY CITY CAPITAL LLC	3/4/5	10%+ Owner	— class O/S missing	1,129,490	$937,477	—	26 Oct 2021	3/4/5
Merck KGaA	3/4/5	10%+ Owner	— class O/S missing	680,825	$565,085	—	26 Oct 2021	3/4/5
BALYASNY ASSET MANAGEMENT L.P.	13F	Company	0.46%	338,542	$365,625	—	31 Mar 2024	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.34%	249,446	$269,000	—	31 Mar 2024	13F
MORGAN STANLEY	13F	Company	0.3%	221,905	$239,657	—	31 Mar 2024	13F
FIL Ltd	13F 3/4/5	Company · Other*	0.3%	218,705	$236,201	—	31 Mar 2024	13F 3/4/5
Alexandria Venture Investments, LLC	3/4/5	10%+ Owner	— class O/S missing	166,423	$138,131	—	26 Oct 2021	3/4/5
Simon M. Tomlinson	3/4/5	10%+ Owner	— class O/S missing	131,117	$108,827	—	21 Oct 2021	3/4/5
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.12%	84,826	$91,650	—	31 Mar 2024	13F
John Charles Williams	3/4/5	10%+ Owner	— class O/S missing	100,080	$83,066	—	21 Oct 2021	3/4/5
Of Ulrich Rodeck Estate	3/4/5	10%+ Owner	— class O/S missing	100,080	$83,066	—	21 Oct 2021	3/4/5
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.1%	71,081	$76,767	—	31 Mar 2024	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.1%	70,198	$75,814	—	31 Mar 2024	13F
Timothy P. Clackson	3/4/5	10%+ Owner	— class O/S missing	90,956	$75,493	—	21 Oct 2021	3/4/5
BlackRock Finance, Inc.	13F	Company	0.06%	45,355	$48,983	—	31 Mar 2024	13F
SevenBridge Financial Group, LLC	13F	Company	0.04%	31,000	$36,580	—	31 Mar 2024	13F
PFG Investments, LLC	13F	Company	0.04%	30,000	$32,400	—	31 Mar 2024	13F
PRELUDE CAPITAL MANAGEMENT, LLC	13F	Company	0.04%	29,500	$31,860	—	31 Mar 2024	13F
FNY Investment Advisers, LLC	13F	Company	0.04%	27,500	$29,000	—	31 Mar 2024	13F
NORTHERN TRUST CORP	13F	Company	0.02%	17,798	$19,222	—	31 Mar 2024	13F
Summit Trail Advisors, LLC	13F	Company	0.02%	16,000	$17,280	—	31 Mar 2024	13F
STATE STREET CORP	13F	Company	0.02%	15,690	$16,945	—	31 Mar 2024	13F
Dunhill Financial, LLC	13F	Company	0.01%	10,274	$15,719	—	31 Mar 2024	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.02%	11,925	$12,879	—	31 Mar 2024	13F
Tower Research Capital LLC (TRC)	13F	Company	0.02%	11,153	$12,045	—	31 Mar 2024	13F
Rachel Humphrey	3/4/5	Director	— class O/S missing	9,444	$7,839	—	21 Oct 2021	3/4/5
JPMORGAN CHASE & CO	13F	Company	0%	2,744	$2,964	—	31 Mar 2024	13F
ROYAL BANK OF CANADA	13F	Company	0%	533	$1,000	—	31 Mar 2024	13F
Key FInancial Inc	13F	Company	0%	830	$896	—	31 Mar 2024	13F
UBS Group AG	13F	Company	0%	201	$217	—	31 Mar 2024	13F
WELLS FARGO & COMPANY/MN	13F	Company	0%	108	$117	—	31 Mar 2024	13F
Qube Research & Technologies Ltd	13F	Company	0%	4	$4	—	31 Mar 2024	13F
Martin H. Huber Jr.	3/4/5	PRESIDENT AND HEAD OF R&D	— class O/S missing	136,500	—	—	16 Aug 2023	3/4/5
Salvatore Giovine	3/4/5	CHIEF FINANCIAL OFFICER	— class O/S missing	49,500	—	—	22 Feb 2022	3/4/5
Edward C. English	3/4/5	PRINCIPAL ACCOUNTING OFFICER	— class O/S missing	24,000	—	—	01 Jan 2023	3/4/5
Michael Jay Ross	3/4/5	Director	— class O/S missing	13,200	—	—	15 Jun 2022	3/4/5
Tomas J. Heyman	3/4/5	Director	— class O/S missing	13,200	—	—	12 Jun 2023	3/4/5

Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q2 2024

As of 30 Jun 2024, Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) was held by 31 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 14,508,823 shares. The largest 10 holders included Bain Capital Life Sciences Investors, LLC, Rock Springs Capital Management LP, TAKEDA PHARMACEUTICAL CO LTD, RiverVest Venture Management LLC, FMR LLC, MORGAN STANLEY, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, Balyasny Asset Management L.P., and FIL Ltd. This page lists 31 institutional shareholders reporting positions in this security for the Q2 2024 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2024 vs Q1 2024 Across Filers

Q1 2024 holders

Q2 2024 holders

Holder diff

Investor	Q1 2024 Shares	Q2 2024 Shares	Share Diff	Share Chg %	Q1 2024 Value $	Q2 2024 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.